

Special Issue

Development and Challenges of Respiratory Disease Vaccines

Message from the Guest Editor

The respiratory system is susceptible to pathogens. Currently, vaccines are available for respiratory diseases such as influenza, COVID-19, pneumonia, pertussis, and tuberculosis (TB). Some infectious respiratory diseases do not yet have a vaccine, such as respiratory syncytial virus (RSV) and the common cold. There are still many troubling issues with existing respiratory vaccines, such as the mutants of influenza virus and SARS-CoV-2; therefore, the development of universal vaccines is now a common concern. As for the RSV vaccine, vaccine-induced pathology is a big safety hurdle. To achieve a more extensive understanding of recent scientific knowledge and current trends in the development of vaccines that protect against respiratory disease, this Special Issue is focused on the recent scientific and technical progresses made in this field. Based on your extensive knowledge and experience, we invite you to contribute research works which highlight (i) correlates of protection, (ii) the action mechanism of novel vaccine candidates, (iii) vaccine protection and vaccine pathology, and (iv) the development of novel attenuated or universal respiratory disease vaccines.

Guest Editor

Prof. Xiaoming Yang

National Engineering Technology Research Center for Combined Vaccines, Wuhan, China

Deadline for manuscript submissions

closed (31 January 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/132877

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).